Why Science Wants You To Take Magic Mushrooms – And Want Canada To Legalize Them

Scientists: Magic mushrooms help people;  What about LSD?  Clapway

As anecdotal evidence continues to grow for the beneficial effects of microdosing mushrooms, Canadian medical experts are pushing for special dispensation.

Healthcare providers and researchers around the world have been pushing for greater access to psychedelics. No, not because they want to be enlightened at a festival this weekend, but because they believe it could be the next breakthrough treatment for the millions of people with mental health problems worldwide. Canadian health care workers resign. Lobbying Health Canada in a big way to overhaul the outdated restrictions imposed on psychedelic drugs. Although the country became one of the first to legalize recreational marijuana use nationwide in 2018, many believe that legalizing psychedelics could be the next step in creating a kinder and more balanced world.

Last August, Canada’s health minister authorized the treatment of four terminally ill cancer patients with psychedelic therapy, with incredibly positive results. This led to further calls for more relaxed policies on the practice and use of resources. Microdosing, Canada has yet to legalize, but it is being practiced frequently, with more users trying this DIY hack every day. Authorities seemed baffled at this point, with few negative enforcements on the material long favored by religious ceremonies and those seeking better mental fitness. To the point where researchers are now starting to hone governments because the results seem too good to ignore.

A growing body of evidence

While research into psychedelics seemed to be gaining momentum in the early 20th century, the brakes were firmly on the brakes in the 1970s. While many tend to attribute this discontinuation of the study to the cold and often outdated regulations being enforced by the government at the time, there is also significant evidence that outdated psychedelic research is being conducted in an unethical manner – resulting in extremely negative and long-term harm to some patients who received these substances without informed consent. Early researchers also applied psychoactive substance use to participants who had underlying psychosis, or other forms of mental illness where the use of psychedelics is considered contraindicated.

However, nearing the 2020s, psychedelic research once again began to gain public favor. As new, stricter, ethical guidelines were adopted and researchers seemed to have a more focused approach to potential therapeutic applications coupled with better pre-screening protocols. These more rigorous research methods have led to very positive results. Research shows that psychedelics such as psilocybin-containing mushrooms, lysergic acid diethylamide (LSD), and DMT may have far-reaching potential in treating historically intractable mental problems such as addiction, depression, trauma and anxiety.

In 2018, the US, Canada, and the UK all relaunched psychedelic research, particularly aimed at alleviating the pain of terminal illnesses such as cancer and treating otherwise drug-resistant addictions to alcohol.

Use Scenarios for Psilocybin, Microdosing, Canada End of Life Care

Driven by a public subculture that self-reported the tremendous mental benefits of mushroom microdosing, Canada has once again been asked to re-evaluate their bans on medicinal and recreational use of psychedelics. Especially as the novel coronavirus has wreaked havoc on the mental health of its citizens, with little infrastructure of the support needed to meet such widespread demand.

Both the UK and US have published studies outlining the therapeutic benefits of psychopharmacology, despite psilocybin still being illegal in both countries. However, many legislators and citizens expect these restrictions to ease, both in Canada and abroad – especially since many psychedelics have an extremely high therapeutic index – meaning the potential for both abuse and side effects (such as overdose) is extremely rare, or incredibly low.

Global pressure mounts as more microdoses – Canada and beyond

Even less likely when patients are microdosing. Canada forums devoted to microdosing psilocybin are full of the positive experiences and purported benefits of using psilocybin in this way. Microdosing is taking small, subhallucinogenic doses of the substance on a routine schedule. So small, in fact, that these microdoses not only allow users to function normally, but most say that while the result is incredibly beneficial, the treatment is virtually unnoticeable.

This is largely because psychedelics, even in small amounts, have been found to promote neuroplasticity and the growth of brain tissue. Types of psychedelics have been shown to bind to the serotonergic system, something many common antidepressants strive for but fail to do. They are also believed to contribute to “ego resolution,” a phenomenon best described as “enabling people to get out of their own way,” by interacting with the dopaminergic system to create radical and self-sabotaged thoughts and feelings. to calm down.

Microdosing has become the next popular wave in the brain-teasing movement. With an overwhelming number of users reporting high levels of motivation, physical energy, improved cognition, and more stable emotional balance. And all without having to set aside time for a full psychedelic “trip”. The idea that small amounts of the popular recreational psychedelics could reasonably provide large benefits is a new gateway to equal access to mental health systems. Now that the benefits far outweigh the risk, it’s time we asked ourselves why these substances were ever banned in the first place.

Show Love ❤️